TPG Weighs $5B Sale of Healthcare Software Firm Lyric

Private equity firm TPG is evaluating a potential sale of Lyric, a healthcare software company it owns, at a valuation of approximately $5 billion, according to reporting from Reuters. The move signals continued investor appetite for health technology assets even as broader dealmaking remains cautious in a high-interest-rate environment.

Lyric operates in the healthcare revenue cycle management and software space — a segment that has attracted sustained strategic and financial interest due to the complexity of medical billing and the ongoing push by health systems to automate administrative workflows. A $5 billion price tag would represent a significant exit for TPG, underscoring how valuable scaled healthcare IT platforms have become to both strategic acquirers and rival private equity buyers.

Read more GM Pursues U.S. Battery Development Amid China Supply Chain Tensions →

For TPG, the exploration of a sale fits a broader pattern among large buyout firms seeking to monetize portfolio companies accumulated during the low-rate era, when cheap debt made leveraged acquisitions far easier to execute. With financing costs now elevated, sellers like TPG face pressure to demonstrate that assets can command premium valuations even in a tighter capital market — and a process at this scale would test that thesis directly.

The healthcare software sector has remained one of the more resilient corners of enterprise technology, driven by regulatory complexity, sticky customer relationships, and multi-year contracts with hospital systems and insurers. Should a deal materialize, it would rank among the larger healthcare IT transactions in recent memory and could attract interest from strategic players in the payer and provider technology ecosystems, as well as other large-cap private equity firms.

Continue reading at SeekingAlpha.